Protara Therapeutics (NASDAQ: TARA) adds Funicular Funds to 21.7M-share resale

Rhea-AI Filing Summary

Protara Therapeutics, Inc. filed a prospectus supplement updating its existing resale registration covering up to 21,686,760 shares of common stock. These shares include currently held common stock as well as shares issuable upon exercise of pre-funded warrants and common warrants held by selling stockholders.

The update adds Funicular Funds, LP as a selling stockholder following an assignment on January 28, 2026 by OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 common stock warrant shares. Funicular Funds, LP does not own common stock as of January 30, 2026 and is subject to a 4.99% beneficial ownership limitation after warrant exercises.

Filed Pursuant to Rule 424(b)(7)

Registration No. 333-279067

PROSPECTUS SUPPLEMENT

(To Prospectus dated May 9, 2024)

 

21,686,760 shares of Common Stock

Unless otherwise stated, all references in this prospectus supplement to “we,” “us,” “our,” “Protara,” the “Company” and similar designations refer to Protara Therapeutics, Inc.

This prospectus supplement updates the prospectus dated May 9, 2024, relating to the resale, from time to time, by the selling stockholders identified in the prospectus, or, the selling stockholders of up to 21,686,760 shares of our common stock, par value $0.001 per share, (“common stock”) consisting of (i) 9,143,380 shares of common stock held by the selling stockholders (“Initial Shares”), (ii) 1,700,000 shares of common stock (“Pre-Funded Warrant Shares”) issuable upon the exercise of pre-funded warrants held by certain of the selling stockholders (“Pre-Funded Warrants”) and (iii) 10,843,380 shares of common stock (“Common Warrant Shares”) issuable upon the exercise of warrants held by the selling stockholders (“Common Warrants”). The Initial Shares, Pre-Funded Warrant Shares and Common Warrant Shares shall be collectively referred to as the “Securities” or the “Shares.”

Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” on page 8 of the accompanying prospectus and any similar section contained in this prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement or the accompanying prospectus.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS ARE TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus supplement is January 30, 2026.

SELLING STOCKHOLDERS

The following information supplements the information set forth under the caption “Selling Stockholders” in the accompanying prospectus. This prospectus supplement includes information with respect to selling stockholders not previously listed in the prospectus.

The following table sets forth information, as of January 30, 2026, with respect to the selling stockholder named below, regarding the number of shares of common stock acquired, or acquirable, by such selling stockholder as a result of an assignment on January 28, 2026 by OTA Trading Fund 1 LLC to Funicular Funds, LP of Common Warrants exercisable for up to 142,400 Warrant Shares. Such information is based on information provided by or on behalf of the selling stockholder and is accurate to the best of our knowledge as of January 30, 2026.

The number of shares in the column “Number of Shares of Common Stock Owned As of the Date Hereof” represents the number of shares of common stock that are actually owned as of the date of this prospectus supplement, and does not represent the number of shares that such selling stockholder may otherwise be obligated to report as “beneficially owned” by such selling stockholder under other rules of the SEC. Please refer to the section titled “Security Ownership of Certain Beneficial Owners and Management” in our Proxy Statement for our 2025 Annual Meeting of Stockholders filed with the SEC on April 25, 2025 for information regarding beneficial ownership.

The table set forth under the caption “Selling Stockholders” in the accompanying prospectus is hereby supplemented as follows:

Name and Address		Number of Shares of Common Stock Owned As of the Date Hereof				Number of Shares of Common Stock Offered Hereby				Number of Shares of Common Stock Underlying Warrants Offered Hereby				Number of Shares of Common Stock Owned After the Offering of All Common Stock Offered Hereby				Percentage of Shares of Common Stock to be Owned by Selling Stockholder After the Offering of All Common Stock Offered Hereby				Beneficial Ownership Limitation
Funicular Funds, LP(17) 601 California Street, Suite 1151 San Francisco, CA 94108			—				—				142,400				—				—				4.99	%

⁽¹⁷⁾ Cable Car Capital, LP, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital, LP, may each be deemed to have voting or investment control over the Shares.

FAQ

What does Protara Therapeutics (TARA) register in this 424B7 supplement?

Protara updates a resale registration for up to 21,686,760 common shares. The registration covers existing shares, plus shares issuable from pre-funded warrants and common warrants, enabling named selling stockholders to resell these securities over time, subject to applicable securities laws.

Who is the new selling stockholder added for Protara Therapeutics (TARA)?

Funicular Funds, LP is added as a new selling stockholder. It appears following an assignment on January 28, 2026 from OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 shares of Protara common stock, all included in the existing resale registration.

How many Protara Therapeutics (TARA) shares can Funicular Funds, LP resell?

Funicular Funds, LP may resell up to 142,400 common warrant shares. These shares are issuable upon exercise of common warrants assigned from OTA Trading Fund 1 LLC and are part of the overall 21,686,760-share resale registration already in place for Protara’s common stock.

Does Funicular Funds, LP currently own Protara Therapeutics (TARA) common stock?

The table shows Funicular Funds, LP with no common shares owned as of January 30, 2026. Its interest consists of warrants exercisable for up to 142,400 common shares, which are registered for potential resale under the updated prospectus supplement.

What is the 4.99% beneficial ownership limitation for Protara (TARA)?

Funicular Funds, LP is subject to a 4.99% beneficial ownership limitation. This provision restricts warrant exercises so that, after giving effect to any exercise, the holder’s beneficial ownership of Protara common stock does not exceed 4.99% of the outstanding shares.

Is Protara Therapeutics (TARA) issuing new shares in this supplement?

The supplement updates a resale registration for existing and warrant-linked shares. It describes shares already outstanding plus shares issuable upon warrant exercises by selling stockholders, rather than describing a new direct primary issuance by Protara in this specific update.